Skip to main content

Search

Reset all filters
594 Result(s)
Sort by

Winners of 2020 BVDzero Case Awards

Winners of 2020 BVDzero Case Awards

Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Trailr2-cdh17-antibody-phase1-trial

Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
New vaccine against Bovine Respiratory Disease

New vaccine against Bovine Respiratory Disease

Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Data Science

Data Science

Revolutionizing research and development with data driven insights
Our partners Bioveta

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
World Veterinary Day aspects veterinary profession

World Veterinary Day aspects veterinary profession

• World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
LastMile – improving through digital

LastMile – improving through digital

LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Access to Healthcare Strategy Sustainable Access Models

Access to Healthcare Strategy Sustainable Access Models

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Dortmund

Dortmund

The Boehringer Ingelheim microParts GmbH in Dortmund manufactures and advances the technology of the RESPIMAT®.
Biberach

Biberach

The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Labor & Human Rights

Labor & Human Rights

Suppliers shall support and respect the protection of internationally proclaimed human rights.
Outside the lab…inside the family

Outside the lab…inside the family

We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Cities join forces for stroke care improvements

Cities join forces for stroke care improvements

Learn how Angels Cities unite to swiftly address stroke symptoms. Quick collaboration saves crucial minutes, minimizing stroke’s devastating effects.